Head and neck cancer has ushered in a new breakthrough in treatment that has not been expected in a decade

On December 11th, the official website of China's State Drug Administration (NMPA) showed that the Merca East PD-1 inhibitor Paboliju monoanti (commodity name: Corida) had been approved for use in assessing tumor expression PD through fully validated testing -L1 (comprehensive positive score (CPS)≥20) metastatic or non-removable relapsed head and neck squamous cell carcinoma (HNSCC) patients first-line treatment, became the first immune first-line treatment of head and neck squamous cancer.
head and neck cancer includes oral cancer, pharynx cancer, throat cancer, nasal cancer and salivary gland tumors, subdivided also includes tongue cancer, tonsil cancer and other sub-types.
90 per cent of all patients with head and neck cancer are squamous cell carcinoma.
smoking and frequent alcohol consumption can increase the risk of head and neck cancer.
estimates that more than 137,000 new cases of head and neck cancer were diagnosed in China in 2018, and nearly 70,000 deaths from head and neck cancer.
early stage head and neck squamous cancer can be treated by surgery or radiotherapy.
but nearly 80% of patients with head and neck squamous cancer are already in the local late stage or metastatic stage at the time of diagnosis and need to be added with comprehensive treatment and medication.
"In China, the number of newly diagnosed cases of head and neck cancer each year has exceeded 137,000, and their bodies are plagued by disease," said Professor Guo Wei, deputy director of the Oncology Department and director of the Phase I Clinical Trials Center at Shanghai Oriental Hospital.
treatment is difficult because of the lack of treatment other than chemotherapy for advanced head and neck cancer.
" The harm of "underestimated head and neck tumors" head and neck tumors has long been easily underestimated.
On the one hand, head and neck tumors contain a variety of tumors, such as lip and mouth cancer, mouth and pharynx cancer, pharynx cancer, nasopharyngeal cancer, throat cancer and salivary gland tumors, the overall incidence rate is not low, and increased year by year.
same time, the most important pathological type of head and neck tumor is squamous cancer, traditional drug treatment is not effective, easy to relapse after treatment, recurrence or metastatic head and neck tumor 5-year survival rate of only 3.6%.
And the location of head and neck tumors, the density of important organs, tumors and traditional treatment may affect the patient's language function and feeding function, resulting in deterioration of the quality of life and prognostics of patients, the urgent need for new drugs to provide patients with better treatment options.
, Professor Guo Wei, said:
Most of the organs connected to the outside world have scaly overskin cover, which can also cause cancer to develop into squamous cancer.
such as tongue cancer in the mouth, tonsil cancer, and even throat cancer down.
, squamous cancer is more suitable for immunotherapy, and there are many studies on head and neck squamous cancer that have shown it to be closely related to immune escape.
if immunotherapy can reverse the immune escape of tumors, it can be a huge success in head and neck squamous cancer.
" head and neck squamous cancer ushered in a decade of unprecedented double breakthrough Early head and neck squamous cancer can be operated on or radiotherapy to allow some patients to achieve the effect of cure.
but nearly 80% of patients with head and neck squamous cancer are already in the local late stage or metastatic stage at the time of diagnosis and need to be added with comprehensive treatment and medication.
To take first-line treatment as an example, from the initial chemotherapy monodrup, to chemotherapy combination program, to targeted drug combination chemotherapy program, until recent years approved immunotherapy, head and neck squamous cancer drug treatment has undergone several stages of evolution.
-line treatment is the first drug treatment option chosen and is currently the most effective and safe treatment for the disease.
This year, China's head and neck squamous cancer patients ushered in a decade of unprecedented good news, first in the United States and Europe has been listed for more than a decade of targeted drug combination chemotherapy program was finally approved in China, and then the latest immune first-line treatment program also accelerated into the domestic, Chinese patients have more treatment options.
addition to treatment, we now see the possibility of preventing and eliminating head and neck squamous cancer.
main causes of head and neck squamous cancer, in addition to recognized tobacco and alcohol, there are long-term infections of the human papillomavirus (HPV).
, the FDA approved the nine-priced HPV vaccine for the prevention of HPV-related oral and neck cancers and head and neck tumors, and humans are expected to achieve a major breakthrough from treatment to prevention through the HPV vaccine and regular screening to completely eliminate HPV-related head and neck tumors in the future.
improved four-year survival rate by nearly three times over four years, and long-term data on head and neck squamous cancer from immunotherapy were encouraging at a recent cancer conference.
In patients with head and neck squamous cancer who were positive for PD-L1, the percentage of patients who were still alive in the fourth year of treatment was almost three times that of the standard program.
Paboli pearl monoantigen not only achieved a breakthrough improvement of nearly three times the four-year survival rate in the first-line treatment of head and neck squamous cancer, but also received consistent recommendations from authoritative guidelines in China and the United States.
this approval also fills the gap in china's first-line immunotherapy for head and neck squamous cancer, bringing long-term efficacy and new hope for long-term survival for more Chinese patients.
, the number of newly diagnosed cases of head and neck cancer has exceeded 137,000 a year, and their bodies are plagued by disease, " says Prof Guo, a professor at the University of China.
treatment is difficult because of the lack of treatment other than chemotherapy for advanced head and neck cancer.
today, the approval of Pabliju monodrausic drugs offers patients a completely new first-line treatment that significantly reduces the risk of death compared to chemotherapy, a standard treatment.
"